BIOMARKER FOR PREDICTING SENSITIVITY OF RECTAL CANCER TO TREATMENT WITH AN0025 IN COMBINATION WITH RADIOTHERAPY/CHEMORADIOTHERAPY (RT/CRT)

Title:

BIOMARKER FOR PREDICTING SENSITIVITY OF RECTAL CANCER TO TREATMENT WITH AN0025 IN COMBINATION WITH RADIOTHERAPY/CHEMORADIOTHERAPY (RT/CRT)

Document Type and Number:

WIPO Patent Application WO/2024/027599

Kind Code:

A1

Abstract:

The present invention provides use of IL-1 alpha, IL-4, IL-18, IL-27a, EGF, HGF, VEGF-D, SCF, IFN-gamma, and MCP-1 (CCL2) or CCL11 (Eotaxin) in blood samples and CD8, CD3&CD8 and CD3&CD8&PD-1 in tumor tissue samples of a rectal cancer patient as a biomarker for predicting the sensitivity of the patient to treatment with AN0025 in combination with radiotherapy/chemoradiotherapy (RT/CRT), and steps thereof, as well as a method for predicting the sensitivity of a rectal cancer patient to treatment with AN0025 in combination with radiotherapy/chemoradiotherapy (RT/CRT) and a method for treating a rectal cancer patient by means of the use.

More Like This:

WO/2004/004729	UTILIZATION OF HETEROARENE CARBOXAMIDE AS DOPAMINE-D3 LIGANDS FOR THE TREATMENT OF CNS DISEASES
WO/2013/110120	PEPTIDE AGENTS FOR CANCER THERAPY
JP5719298	Recombinant anti-epithelial growth factor receptor antibody composition

Inventors:

LIANG HONGMING (CN)
LU XUYANG (CN)
LAUTERMILCH NATHAN (US)
ATKINSON ROBERT (US)
TANG KAIYANG (CN)

Application Number:

PCT/CN2023/109888

Publication Date:

February 08, 2024

Filing Date:

July 28, 2023

Export Citation:

Click for automatic bibliography generation Help

Assignee:

ADLAI NORTYE BIOPHARMA CO LTD (CN)

International Classes:

A61P35/00; C12Q1/6886; C12Q1/68; G01N33/574; G01N33/68

Domestic Patent References:

WO2022138793A1

2022-06-30

Foreign References:

CN106572993A	2017-04-19
CN103097358A	2013-05-08
US20100008955A1	2010-01-14
CN111295394A	2020-06-16
CN108387731A	2018-08-10
JP2018155506A	2018-10-04
US20150118252A1	2015-04-30

Other References:

JIANG W, DOU S, LI R, ZHANG L, ZHU G: "1147P - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas", ANNALS OF ONCOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 30, no. suppl 5, 1 October 2019 (2019-10-01), GB , pages v465, XP093044388, ISSN: 1569-8041, DOI: 10.1093/annonc/mdz252

Attorney, Agent or Firm:

FONDEE IP LAW LLC (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: DATA TRANSMISSION METHOD AND APPARATUS, STORAGE MEDIUM, AND ELECTRONIC DEVICE

Next Patent: SEMI-FINISHED WATERPROOF DEVICE AND MANUFACTURING METHOD THEREFOR, AND FINISHED WATERPROOF DEVICE